De Novo Classification: Regulatory Pathway for Novel Devices

QNova LifeSciences helps biotech and medtech innovators navigate the FDA De Novo classification process — turning novel medical devices into market-ready solutions.

• 250+ FDA device submissions with a 100% success rate
• 65+ successful FDA NDA, BLA, 505(b)(1), and 505(b)(2) filings
• 30+ FDA special designations granted for innovative products
• Expertise across therapeutics, biologics, diagnostics, and complex devices

Whether you are pursuing a first-in-class device or transitioning from a 510(k) NSE, our integrated regulatory and clinical consulting ensures you achieve market entry efficiently and strategically.

Introduction to De Novo Classification

The FDA De Novo classification pathway was designed for low-to-moderate-risk medical devices without an existing predicate.

• Purpose: Establishes a new Class I or Class II classification for novel devices.
• Impact: Creates a new product code, which can later be used as a predicate in 510(k) submissions.
• Regulatory Framework: Formalized by the 2021 FDA final rule under the FD&C Act.

QNova guides clients through every step — from initial feasibility assessment to postmarket compliance — ensuring devices meet FDA expectations for safety, effectiveness, and risk management.

When is a De Novo Request Applicable?

You may be eligible for De Novo classification if your device:

• Has no existing predicate device.
• Falls within low-to-moderate risk where general or special controls are sufficient.
• Was first submitted under 510(k) and determined Not Substantially Equivalent (NSE).

Why Pre-Submission Matters

The FDA encourages Pre-Submission (Q-Sub) meetings for early feedback on:

• Required test methods
• Applicable regulatory controls
• Clinical study design expectations

QNova Advantage: We have a proven track record in FDA meeting preparation, drafting Q-Subs, and ensuring successful FDA interactions.

Device Classification Framework

FDA uses a risk-based classification system (FD&C Act Section 513):

• Class I (Low–Moderate Risk): General controls only (e.g., GMPs, labeling, recall reporting).
• Class II (Moderate–High Risk): Requires special + general controls (e.g., performance standards, postmarket surveillance, registries, labeling).
• Class III (High Risk): Requires PMA due to insufficient controls.

QNova provides gap assessments, predicate evaluations, and regulatory strategy design to confirm the correct pathway and prevent unnecessary delays.

De Novo vs. PMA Pathways

While both De Novo and PMA involve FDA review, they differ significantly in risk, cost, and complexity.

Feature	De Novo	PMA
Risk Level	Low–Moderate	High
FDA Controls	General/Special	PMA (most rigorous)
Clinical Data	Often required, but less than PMA	Extensive, multi-phase trials
FDA Review Time	~150 FDA Days goal	180+ Days
Fees (FY2025)	~$162K (Std) / $40K (Small Biz)	~$540K (Std) / $135K (Small Biz)
Predicate Use	Becomes predicate for 510(k)	N/A

QNova’s Role: We help determine whether 510(k), De Novo, or PMA is the right path based on your device profile, available data, and market strategy.

[Placeholder for Client Review: Confirm if QNova supports full PMA consulting services in addition to De Novo]

De Novo Submission Process

Required Submission Content

• Administrative cover sheet
• Device description (including intended use and design)
• Non-clinical testing (bench, animal, biocompatibility, EMC, software validation)
• Clinical data (if applicable)
• Benefit-risk analysis
• Compliance with the Acceptance Checklist for De Novo Requests

Submission Methods

• eSTAR: Interactive PDF template (FDA’s preferred method for standardization and completeness).
• eCopy: Legacy option using CD/DVD with signed cover letter.

User Fees

• Must be paid before submission.
• Reduced fees available for qualified small businesses.

QNova provides full-service regulatory writing, submission formatting, and FDA liaison services, ensuring all data packages meet the required standards.

De Novo Review Process

The FDA follows a two-stage review:

1. Acceptance Review (15 days): Confirms completeness against checklist.
   • If incomplete → FDA issues RTA (Refuse to Accept) hold (up to 180 days for sponsor to respond).
2. Substantive Review: Evaluates risk classification, adequacy of data, and safety/effectiveness under general/special controls.

If successful, the device receives Class I or II classification and a new regulation number.

QNova’s support: We help clients manage FDA deficiency responses, avoid common pitfalls, and maintain momentum during review.

De Novo Review Timelines

Historical Context

• Before 2012: Only possible after a failed 510(k).
• After 2012: Direct De Novo submissions allowed.
• 2021 Final Rule: Set review goal of 120 calendar days (not often met).

Current Performance Goals

• FDA target: 70% of De Novo submissions decided within 150 FDA Days.
• Real-world: Average ~307 calendar days (range: 108–619).

Challenges Affecting Timelines

• FDA Days ≠ Calendar Days (excludes RTA/AI hold times).
• Limited transparency — only granted requests are publicly visible.
• Covid-19 and resource constraints have extended timelines.

QNova accelerates timelines with:

• Early testing plan submissions to FDA
• Pre-Submission strategy alignment
• Modular review planning (similar to PMA modulars)

Improvements and Challenges

Recent Enhancements

• eSTAR adoption (fewer deficiencies, faster reviews).
• Standardization of submissions for easier FDA review.

Proposed Improvements

• Third-party reviews for 510(k)-like sections (e.g., sterilization, biocompatibility, EMC testing).
• Modular review (allowing FDA to review non-clinical data before clinical studies complete).
• Mandatory pre-submission of testing protocols.

QNova offers regulatory strategy consulting, clinical trial project management, and QMS services, positioning clients ahead of anticipated FDA trends.

Advantages of the De Novo Pathway

• Streamlined pathway for novel devices without predicates.
• Establishes a new classification and regulation.
• Device can serve as a future predicate for future 510(k) submissions.
• Lower FDA fees than PMA.
• Greater flexibility for postmarket modifications.
• Reduces investor risk by providing a defined FDA pathway.

Postmarket Requirements

De Novo Devices

• Once approved, future modifications generally follow 510(k) requirements.
• FDA guidance outlines when to submit a new 510(k) for changes.

QNova provides Quality Management Systems (QMS), audits, and compliance support to help companies meet evolving FDA postmarket expectations.

Regulatory Submission Strategy

Factors to consider when choosing your regulatory pathway:

• Device risk level (low/moderate vs. high).
• Availability of a predicate.
• Budget and resource constraints.
• Target markets beyond the U.S.

QNova offers end-to-end regulatory solutions, including:

• Risk management strategy development
• Regulatory due diligence for investors and partners
• FDA communication strategy and representation at meetings
• Global expansion planning (CE Mark, ROW submissions)

Frequently Asked Questions (FAQs)

Q: What is a De Novo classification request?
A regulatory pathway for novel, low-to-moderate-risk devices without a predicate.

Q: How long does FDA review take?
While the FDA’s goal is 120 days, most reviews take 9–12 months.

Q: Can a De Novo device serve as a predicate?
Yes. Once classified, it establishes a new regulation usable for future 510(k)s.

Q: What’s the difference between De Novo and PMA?
De Novo is streamlined for low/moderate risk; PMA is required for high-risk devices and involves extensive data.

Q: How does QNova help?
We provide regulatory consulting, FDA meeting prep, submission management, clinical trial support, and commercialization strategy to ensure De Novo success.

Why Partner with QNova LifeSciences?

• Proven FDA Success: Over 250 FDA device submissions, 100% success rate.
• Expert Team: Specialists across therapeutics, diagnostics, and devices.
• Integrated Model: On-demand development team, milestone-based strategies.
• Global Reach: Expertise in U.S. FDA and international regulatory markets.
• Commercialization Support: Investor readiness, U.S. market entry, pricing, and reimbursement strategies.

Explore Related Services

• How We Work
• Expertise Across Therapeutics & Medical Devices
• Contact Our Regulatory Experts